Mutations in the B sub(2) bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists

The B sub(2) bradykinin receptor, a seven-helix transmembrane receptor, binds the inflammatory mediator bradykinin (BK) and the structurally related peptide antagonist HOE-140. The binding of HOE-140 and the binding of bradykinin are mutually exclusive and competitive. Fifty-four site-specific receptor mutations were made. BK's affinity is reduced 2200-fold by F261A, 490-fold by T265A, 60-fold by D286A, and 3-10-fold by N200A, D268A, and Q290A. In contrast, HOE-140 affinity is reduced less than 7-fold by F254A, F261A, Y297A, and Q262A. The almost complete discordance of mutations that affect BK binding versus HOE-140 binding is surprising, but it was paralleled by the effect of single changes in BK and HOE-140. [Ala super(9)]BK and [Ala super(6)]BK are reduced in receptor binding affinity 27,000- and 150-fold, respectively, while [Ala super(9)]HOE-140 affinity is reduced 7-fold and [Ala super(6)]HOE-140 affinity is unchanged. NMR spectroscopy of all of the peptidic analogs of BK or HOE-140 revealed a beta -turn at the C terminus. Models of the receptor-ligand complex suggested that bradykinin is bound partially inside the helical bundle of the receptor with the amino terminus emerging from the extracellular side of helical bundle. In these models a salt bridge occurs between Arg super(9) and Asp super(286); the models also place Phe super(8) in a hydrophobic pocket midway through the transmembrane region. Models of HOE-140 binding to the receptor place its beta -turn one alpha -helical turn deeper and closer to helix 7 and helix 1 as compared with bradykinin-receptor complex models.